Toxic effects of SLE serum on normal monocytes in vitro: cell death induced by apoptosis related to complement dysfunction

Abstract

The aim of this study was to assess toxic effects of systemic lupus erythematosus (SLE) serum on blood peripheral mononuclear cells from healthy donors and to evaluate if complement activation was involved. Monocytes from a healthy donor were incubated with 20 sera from ten SLE patients in both high and low disease activity states. After incubation non-adherent cells were analysed by flow cytometry. Serum from six SLE patients induced an increased cell death, four in active disease only, one in the inactive state and one in the active and the inactive state. Five of these sera, three with high and two with low disease activity, induced an increased apoptosis in the monocytes. Proportion of apoptotic cells correlated inversely with C1q and C3 concentration in the active disease sera, but not with disease activity as evaluated by SLEDAI. Apoptosis could be induced by addition of active C1s or antigen/antibody complexes to normal serum before incubation. Serum with complexes added induced increased tumour necrosis factor-a secretion from mononuclear cells, but SLE patient sera did not.

The results demonstrate that the toxic effect of serum from SLE patients on healthy monocytes is explained by induction of apoptosis. The induction process is suggested to be connected with complement activation in the serum.

Keywords

apoptosis systemic lupus erythematosus mononuclear leukocytes complement antigen–antibody complexes

Get full access to this article

View all access options for this article.

References

Emlen W , Niebur J , Kadera R . Accelerated in vitro apoptosis of lymphocytes from patients with systemic lupus erythematosus . J Immunol 1994; 152: 3685–3692 .

Perniok A , Wedekind F , Herrman M et al. High levels of circulating early apoptotic peripheral blood mononuclear cells in systemic lupus erythematosus . Lupus 1998; 7: 113–118 .

Herrmann M , Voll R , Zoller O et al. Impaired phagocytosis of apoptotic cell material by monocyte-derived macrophages from patients with systemic lupus erythematosus . Arthritis Rheum 1998; 41: 1241–1250 .

Hale AJ , Smith CA , Sutherland LC et al. Apoptosis: molecular regulation of cell death . Eur J Biochem 1996; 236: 1–26 (review).

Casciola-Rosen L , Rosen A , Petri M , Schlissel M . Autoantigens targeted in systemic lupus erythematosus are clustered in two populations of surface structures on apoptotic keratinocytes . J Exp Med 1994; 179: 1317–1330 .

Svensson B , Sturfelt G . Monocyte in vitro function in systemic lupus erythematosus (SLE). II. Glass adherence and spreading in presence of SLE-sera . Scand J Rheumatol 1980; (Suppl 31): 43–52 .

Yang B-C , Wang Y-S , Lin L-C , Liu M-F . Induction of apoptosis and cytokine gene expression in T-cell lines by sera of patients with systemic lupus erythematosus . Scand J Immunol 1997; 45: 96–102 .

Sturfelt G , Sjöholm AG . Complement components, complement activation, and acute phase response in systemic lupus erythematosus (SLE) . Int Arch Allergy Appl Immunol 1984; 75: 75–83 .

Tan EM , Cohen AS , Fries JF et al. The 1982 revised criteria for the classification of systemic lupus erythematosus . Arthritis Rheum 1982; 25: 1271–1277 .

10.

Bombardier C , Gladman DD , Urowitz MB et al and the Committee on Prognosis Studies in SLE. Derivation of the SLEDAI. A disease activity index for lupus patients . Arthritis Rheum 1992; 35: 630–640 .

11.

Sturfelt G , Nived O , Sjöholm AG . Kinetic analysis of immune complex solubilization: complement function in relation to disease activity in SLE . Clin Exp Rheum 1992; 10: 241–247 .

12.

Ma Êrtensson U , Sjöholm AG , Sturfelt G et al. Western blot analysis of human IgG reactive with the collagenous portion of C1q: evidence of distinct binding specificities . Scand J Immunol 1992; 35: 735–744 .

13.

Ganrot PO . Crossed immunoelectrophoresis . Scand J Clin Lab Invest 1972; (Suppl 124): 39–47 .

14.

Yam LT , Crosby WH . Cytochemical identification of monocytes and granulocytes . Am J Clin Pathol 1971; 55: 283–290 .

15.

Svensson B . Methodological studies of monocyte yeast cell phagocytosis . Scand J Rheumatol 1980; (Suppl 31): 5–19 .

16.

Lorenz HM , Grünke M , Hieronymus T et al. In vitro apoptosis and expression of apoptosis-related molecules in lymphocytes from patients with systemic lupus erythematosus and other autoimmune diseases . Arthritis Rheum 1997; 40: 306–317 .

17.

Tsai C-Y , Wu T-H , Sun K-H et al. Polyclonal IgG anti-dsDNA antibodies exert cytotoxic effect on cultured rat mesangial cells by binding to cell membrane and augmenting apoptosis . Scand J Rheumatol 1993; 22: 162–171 .

18.

Nakamura N , Shidara Y , Kawaguchi N et al. Lupus anticoagulant antibody induces apoptosis in umbilical vein endothelial cells: involvement of annexin V . Biochem Biophys Res Commun 1994; 205: 1488–1493 .

19.

Evans MJ , MacLaughlin S , Marvin RD , Abdou NI . Estrogen decreases in vitro apoptosis of peripheral blood mononuclear cells from women with normal menstrual cycles and decreases TNF-alpha production in SLE but not in normal cultures . Clin Immunol Immunopathol 1997; 82: 258–262 .

20.

Botto M , Dell'Agnola C , Bygrave AE et al. Homozygous C1q deficiency causes glomerulonephritis associated with multiple apoptotic bodies . Nat Genet 1998; 19: 56–59 .

21.

Carroll MC . The lupus paradox . Nat Genet 1998; 19: 3–4 .

22.

Eriksson H , Nissen MH . Complement component C1r mediated cleavage of the heavy chain of the major histocompatibility class I antigens . Biochem Biophys Res Commun 1992; 187: 832–838 .

23.

Eriksson H , Nissen MH . Proteolysis of the heavy chain of major histocompatibility complex class I antigens by complement component C1s . Biochim Biophys Acta 1990; 1037: 209–215 .

24.

Yap HK , Ng SC , Lee BW et al. Modulation of MHC expression on human endothelial cells by sera from patients with systemic lupus erythematosus . Clin Immunol Immunopathol 1993; 68: 321–326 .

25.

Puppo F , Indiveri F , Scudeletti M , Ferrone S . Soluble HLA antigens: new roles and uses . Immunol Today 1997; 18: 154–155 .

26.

Hagihara M , Shimura T , Yamamoto K et al. Clinical significance of serum soluble HLA class I antigens in systemic lupus erythematosus . Tokai J Exp Clin Med 1993; 18: 61–64 .

27.

Tsuchiya N , Shiota M , Yamaguchi A , Ito K . Elevated serum levels of soluble HLA class I antigens in patients with systemic lupus erythematosus . Arthritis Rheum 1996; 39: 792–796 .

28.

Bresciani A , Pirozzi G , Spera M et al. Increased level of serum HLA class I antigens in patients with systemic lupus erythematosus. Correlation with disease activity . Tissue Antigens 1998; 52: 44–50 .